Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes

• Published in: The journal of clinical endocrinology and metabolism Vol. 104; no. 7; pp. 2953 - 2960
• Main Authors: Bergmann, Natasha Chidekel, Lund, Asger, Gasbjerg, Lærke Smidt, Jørgensen, Niklas Rye, Jessen, Lene, Hartmann, Bolette, Holst, Jens Juul, Christensen, Mikkel Bring, Vilsbøll, Tina, Knop, Filip Krag
• Format: Journal Article
• Language: English
• Published: Washington, DC Endocrine Society 01.07.2019; Copyright Oxford University Press; Oxford University Press
• Subjects: Analysis; Biotechnology industry; Body weight; Bone growth; Bone resorption; Bone turnover; Collagen; Collagen (type I); Cross-linking; Dextrose; Diabetes mellitus; Ethylenediaminetetraacetic acid; GIP protein; Glucagon; Glucagon-like peptide 1; Glucose; Glucose tolerance; Glucose tolerance tests; Liraglutide; Metabolism; Mimicry; Osteogenesis; Overweight; Overweight persons; Physiological aspects; Procollagen; Type 2 diabetes; Vitamin D; Denmark
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2019-00008

Abstract Context The gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been suggested to play a role in bone metabolism. Exogenous administration of GIP inhibits bone resorption, but the effect of GLP-1 is less clear. Furthermore, the combined effect of exogenous GIP and GLP-1 on bone metabolism is unknown. Objective To investigate the effect of separate and combined infusions of the incretin hormones GIP and GLP-1 on bone resorption and formation. Design Randomized, double-blinded, placebo-controlled, crossover study including five study days. Participants Seventeen overweight/obese men. Interventions On the first study day, a 50-g oral glucose tolerance test (OGTT) was performed. On the next four study days, isoglycemic IV glucose infusions (IIGI), mimicking the glucose excursions from the OGTT, were performed with concomitant infusions of GIP (4 pmol/kg/min), GLP-1 (1 pmol/kg/min), GIP+GLP-1 (4 and 1 pmol/kg/min, respectively), or placebo, respectively. Primary Outcomes Changes in bone resorption assessed by measurements of carboxy-terminal type I collagen crosslinks (CTX) and in bone formation as assessed by procollagen type 1 N-terminal propeptide (P1NP) concentrations. Results During the OGTT, CTX was significantly lowered by 54 ± 13% from baseline (mean ± SD) compared with 28 ± 12% during IIGI + saline (P < 0.0001). During IIGI+GLP-1 and IIGI+GIP, CTX was lowered by 65 ± 16% and 74 ± 9%, respectively, from baseline, whereas IGII+GIP+GLP-1 lowered CTX by 84 ± 4% from baseline. P1NP levels were unaffected by the interventions. Conclusions Our data suggest that GLP-1, like GIP, may be involved in regulation of bone resorption and that GIP and GLP-1 together have partially additive inhibitory effects. In overweight men, infusion of GIP and GLP-1 decreased bone resorption, and coinfusion of the two incretins had partially additive effects on bone resorption.